• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Can a demand for organ transplants overweigh fears?

11.05.2017/in News /by eugeneqqq

According to Global Observatory on Donation and Transplantation organization data, in 2015 in the US were performed 18,597 kidney transplants (57.79 per million inhabitants) which are 22% of all kidney transplant operations worldwide. These numbers seem relatively great; for example, in the same year in Russian Federation were performed only 945 (6.59 per million inhabitants) kidney transplants which are just 1% of kidney transplant surgeries worldwide.

But relative success is not a sign that a problem with organ availability is completely solved as waiting times for kidney transplants exceed 3 to 5 years in many parts of the United States.

An extraordinary solution was recently suggested by Goldberg et al. Since more than 500 high-quality kidneys from deceased donors with hepatitis C virus (HCV) infection are discarded annually and new antiviral agents used to treat HCV are efficient, safe and tolerable, authors considered kidney transplant from HCV-infected donor a clinically feasible option and persuaded 14 patients to consent for such transplant surgery in case of organ from infected donor becomes available before any other kidney. So, 10 of them received HCV-infected kidneys. Median time in waiting list was only 58 days, but median Kidney Donor Profile Index (kidney “quality” measure) was 42% which was considered as an indicator of relatively high risk of graft rejection.

Obviously, all patients had detectable HCV RNA levels post-op, so elbasvir-grazoprevir antiviral therapy was initiated in all patients and all of them were successfully cured of hepatitis C (undetectable viral load on week 12). Transplantation was effective – median estimated glomerular filtration rate at 6 months was 62.8 ml per minute per 1.73 m2.

One might assume that a potential El Dorado of kidney transplants has been found as a result of this tiny and bold study but one patient developed transient new class I donor-specific antibody, one – proteinuria (subject was suffering from IgA-nephropathy before transplant) and in one – focal segmental glomerulosclerosis was detected.

From a study with such small sample size only careful conclusions can be made. But the most important fact aside from obvious necessity to conduct a bigger study is a fact that some proportion of people is ready to consensually get HCV-infected kidney transplants, and this finding is indicative of HCV de-stigmatization in society. Nevertheless, a variety of potential legal problems associated with potential implementation or even further investigation of this approach may seem frightening enough to stop any further research. It would be curious at least to see results of long-term follow-up of patients studied in this trial.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

7 + 1 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
The International Society for Pharmaceutical Engineering establishes its branch... May the force be with you! R2D2 will simplify ophthalmologist-surgeon’s j...
Scroll to top